We are live on ! Find out more
RKDA icon

Arcadia Biosciences
RKDA

15 hedge funds and large institutions have $2.26M invested in Arcadia Biosciences in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 14 → 15 (+1)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

36% less capital invested

Capital invested by funds: $3.53M → $2.26M (-$1.27M)

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LRPA
L. Roy Papp & Associates
Arizona
+$224K
2
VKH
Virtu KCG Holdings
New York
+$26.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$18.4K
4
Creative Planning
Creative Planning
Kansas
+$10K
5
TRCT
Tower Research Capital (TRC)
New York
+$5.58K

Top Sellers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
-$310K
2
BCM
Bridgeway Capital Management
Texas
-$24.5K
3
Norges Bank
Norges Bank
Norway
-$21K
4
BlackRock
BlackRock
New York
-$20.1K
5
Citadel Advisors
Citadel Advisors
Florida
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
WRF
1
Waddell & Reed Financial
Kansas
$1.78M -$310K -555 -10%
LRPA
2
L. Roy Papp & Associates
Arizona
$333K +$224K +402 +77%
Vanguard Group
3
Vanguard Group
Pennsylvania
$30K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$26K +$18.4K +33 +87%
VKH
5
Virtu KCG Holdings
New York
$22K +$26.2K +47 +362%
Creative Planning
6
Creative Planning
Kansas
$20K +$10K +18 +47%
BCM
7
Bridgeway Capital Management
Texas
$18K -$24.5K -44 -47%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$11K – – –
Northern Trust
9
Northern Trust
Illinois
$7K – – –
Goldman Sachs
10
Goldman Sachs
New York
$6K – – –
BlackRock
11
BlackRock
New York
$4K -$20.1K -36 -75%
TRCT
12
Tower Research Capital (TRC)
New York
$4K +$5.58K +10 +1,000%
Deutsche Bank
13
Deutsche Bank
Germany
$1K +$1.67K +3 New
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5 – – –
Norges Bank
15
Norges Bank
Norway
– -$21K -39 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$19K -35 Closed
Morgan Stanley
17
Morgan Stanley
New York
– +$558 +1 New
SPIA
18
Steward Partners Investment Advisory
New York
– +$558 +1 New

RKDA Hedge Fund Activity: Q2 2017 in Review

15 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q2 2017, worth a combined $2.26M — down 36% from $3.53M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RKDA positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.

The largest buyer was L. Roy Papp & Associates, adding an estimated $224K. The largest seller was Waddell & Reed Financial, cutting an estimated $310K.

  • 15 institutional investors held Arcadia Biosciences (RKDA) as of Q2 2017, up from 14 in Q1 2017.
  • Funds reported $2.26M of Arcadia Biosciences stock for Q2 2017, down 36% quarter-over-quarter.
  • 3 funds opened new Arcadia Biosciences positions in Q2 2017 and 2 closed out, a net change of +1 holder.
  • The largest Arcadia Biosciences buyer in Q2 2017 was L. Roy Papp & Associates, an estimated $224K added.
  • The largest Arcadia Biosciences seller in Q2 2017 was Waddell & Reed Financial, an estimated $310K sold.

Based on aggregated 13F filings for Q2 2017.